Sumitomo Pharma Profit Surges on Higher Revenue and Cost Controls

An update from Sumitomo Dainippon Pharma Co ( (JP:4506) ) is now available.

Sumitomo Pharma reported a sharp improvement in earnings for the year ended March 31, 2025, with revenue rising to ¥453.3 billion and operating profit jumping to ¥107.3 billion, driven by higher sales and significantly lower selling, general and administrative expenses. Net profit attributable to owners of the parent surged to ¥106.9 billion, cash flow from operating activities strengthened, and return on equity climbed to 46.3%, underscoring improved profitability and capital efficiency.

The company forecasts further revenue growth to ¥540.0 billion in fiscal 2026, though it expects core operating profit to ease to ¥91.0 billion as cost of sales and R&D spending increase. Management also highlights the impact of foreign exchange movements, with a weaker yen versus the dollar factored into its assumptions, suggesting currency trends and continued investment in development will be key variables for future performance.

The most recent analyst rating on (JP:4506) stock is a Buy with a Yen2700.00 price target. To see the full list of analyst forecasts on Sumitomo Dainippon Pharma Co stock, see the JP:4506 Stock Forecast page.

More about Sumitomo Dainippon Pharma Co

Sumitomo Pharma Co., Ltd. is a Japanese pharmaceutical company operating under IFRS standards and listed under securities code 4506. The group focuses on the research, development, manufacturing and sale of pharmaceuticals, with a development pipeline that includes major products under development and a global footprint reflected in regional gross profit reporting.

Average Trading Volume: 14,271,228

Technical Sentiment Signal: Buy

Current Market Cap: Yen723.6B

For detailed information about 4506 stock, go to TipRanks’ Stock Analysis page.